SIGA Technologies Balance Sheet Health
Financial Health criteria checks 6/6
SIGA Technologies has a total shareholder equity of $169.4M and total debt of $0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are $195.4M and $25.9M respectively. SIGA Technologies's EBIT is $104.6M making its interest coverage ratio -25.2. It has cash and short-term investments of $99.3M.
Key information
0%
Debt to equity ratio
US$0
Debt
| Interest coverage ratio | -25.2x |
| Cash | US$99.27m |
| Equity | US$169.44m |
| Total liabilities | US$25.91m |
| Total assets | US$195.35m |
Recent financial health updates
No updates
Recent updates
SIGA Technologies: Expansion Into mAbs Is Smart, But Eggs Remain In One Basket
Nov 21Investors Shouldn't Be Too Comfortable With SIGA Technologies' (NASDAQ:SIGA) Earnings
Nov 15
SIGA Technologies, Inc. (NASDAQ:SIGA) Not Doing Enough For Some Investors As Its Shares Slump 34%
Sep 14SIGA Technologies: Shares Tanking On Mpox Study Miss, Turbulence May Be Temporary
Aug 15SIGA Technologies, Inc. (NASDAQ:SIGA) Held Back By Insufficient Growth Even After Shares Climb 31%
Jul 14SIGA Technologies: BARDA Contract Renewal Required To Sustain Recent Momentum (Rating Downgrade)
Jun 13SIGA Technologies, Inc. (NASDAQ:SIGA) Stock Rockets 64% But Many Are Still Ignoring The Company
Mar 31Siga Technologies: Preparing For A Contingency If Tomorrow Comes
Mar 25Shareholders Can Be Confident That SIGA Technologies' (NASDAQ:SIGA) Earnings Are High Quality
Mar 19The Price Is Right For SIGA Technologies, Inc. (NASDAQ:SIGA)
Feb 15Do SIGA Technologies' (NASDAQ:SIGA) Earnings Warrant Your Attention?
Jan 13SIGA Technologies secures new contract awarded to procure up to $10.7M of TPOXX
Sep 29Siga monkeypox therapy undergoes NIH-led late-stage trial
Sep 09Scientists behind key COVID study run monkeypox trial for SIGA therapy
Aug 23SIGA to activate first trial sites for monkeypox therapy in U.K. next week – Bloomberg
Aug 17Estimating The Fair Value Of SIGA Technologies, Inc. (NASDAQ:SIGA)
Aug 12SIGA to deliver $26M of monkeypox therapy to U.S. in 2023 after option exercise
Aug 09SIGA Technologies: Unjustified Selloff, Loading The Boat, Best Monkeypox Play
Aug 01SIGA Technologies: Buy Monkeypox
Jul 25Siga Technologies receives approval from UK for tecovirimat
Jul 08SIGA Technologies: Solid Business With Means To Address Monkeypox Outbreak
May 27SIGA Technologies: There's An Assured Market For A Smallpox Vaccine
Dec 12It's Probably Less Likely That SIGA Technologies, Inc.'s (NASDAQ:SIGA) CEO Will See A Huge Pay Rise This Year
Jun 08SIGA Technologies: Biodefense Pharma Unlocks New Value Abroad For TPOXX
Apr 28Introducing SIGA Technologies (NASDAQ:SIGA), The Stock That Soared 880% In The Last Five Years
Feb 22Financial Position Analysis
Short Term Liabilities: SIGA's short term assets ($180.7M) exceed its short term liabilities ($22.3M).
Long Term Liabilities: SIGA's short term assets ($180.7M) exceed its long term liabilities ($3.6M).
Debt to Equity History and Analysis
Debt Level: SIGA is debt free.
Reducing Debt: SIGA has no debt compared to 5 years ago when its debt to equity ratio was 76.7%.
Debt Coverage: SIGA has no debt, therefore it does not need to be covered by operating cash flow.
Interest Coverage: SIGA has no debt, therefore coverage of interest payments is not a concern.